NCT00407407

ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma

A Phase I Dose Escalation Study of ABI-007 With Carboplatin TM as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Celgene · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of this study is to determine the maximum tolerated dose and dose-limiting toxicities (DLTs) of weekly and every 3-weeks ABI-007 in combination with carboplatin (area under the curve \[AUC\]=6) in patients with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

Conditions

• Fallopian Tube Neoplasms
• Peritoneal Neoplasms
• Ovarian Neoplasms

Interventions

Type	Name	Description
DRUG	ABI-007	80mg/m\^2 to 150mg/m\^2 IV every 3 weeks
DRUG	Carboplatin	6 AUC IV every 3 weeks on the same day as ABI-007

Timeline

• Start date: 2006-11-01
• Primary completion: 2008-02-01
• Completion: 2008-02-01
• First posted: 2006-12-05
• Last updated: 2019-10-18

Locations

1 site across 1 country: United States